Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Development, characterization and treatment of a Pex16 mouse model for Zellweger Spectrum Disorder

EF 2022-23

Résumé
Zellweger Spectrum Disorder (ZSD) is caused by mutations in any of 13 PEX genes encoding proteins required for peroxisome formation and function. Defects in PEX16 cause ZSD with central nervous system (CNS) related symptoms including leukodystrophy, spasticity, poor balance and cognitive impairment. There is currently no therapy for this life-limiting disease, making it crucial to develop treatments. To address this, we will study a novel mouse model lacking the Pex16 gene. We will produce a mouse carrying one inactive Pex16 allele and one allele with a Pex16 gene that can be inactivated by administration of the drug tamoxifen. This approach was previously used successfully with the peroxisomal gene Pex5. We hypothesize that similar to patients and fruit fly models with PEX16 mutations, our mice will present with CNS symptoms such as ataxia and decreased motor and cognitive functions once Pex16 is fully inactivated. We will characterize the CNS by testing motor and cognitive functions using Rotarod and Y-maze exams. Brain tissue will be collected for histological analyses, and peroxisome-dependent lipid levels will be quantified. We will then attempt to treat the mouse model with CNS directed gene therapy. We will administer an existing gene replacement vector (scAAV9-HsPEX16) to the brain of our mouse model, which will enter their cells and produce normal PEX16 protein. CNS characterization will then be repeated to determine preclinical efficacy. This project will help us understand the role of PEX16 in the CNS and the feasibility of gene therapy for treating PEX16-mediated ZSD. If effective, the therapeutic approach used in these experiments could be translatable to treating patients with other PEX gene mutations as well as other genetic diseases with CNS involvement.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486305
Name
Gosaine Amrita
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development, characterization and treatment of a Pex16 mouse model for Zellweger Spectrum Disorder
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cns Mouse Model; Gene Therapy; Peroxisome Disorder; Pex16; Tamoxifen; Zellweger Spectrum Disorder
Abstract
Zellweger Spectrum Disorder (ZSD) is caused by mutations in any of 13 PEX genes encoding proteins required for peroxisome formation and function. Defects in PEX16 cause ZSD with central nervous system (CNS) related symptoms including leukodystrophy, spasticity, poor balance and cognitive impairment. There is currently no therapy for this life-limiting disease, making it crucial to develop treatments. To address this, we will study a novel mouse model lacking the Pex16 gene. We will produce a mouse carrying one inactive Pex16 allele and one allele with a Pex16 gene that can be inactivated by administration of the drug tamoxifen. This approach was previously used successfully with the peroxisomal gene Pex5. We hypothesize that similar to patients and fruit fly models with PEX16 mutations, our mice will present with CNS symptoms such as ataxia and decreased motor and cognitive functions once Pex16 is fully inactivated. We will characterize the CNS by testing motor and cognitive functions using Rotarod and Y-maze exams. Brain tissue will be collected for histological analyses, and peroxisome-dependent lipid levels will be quantified. We will then attempt to treat the mouse model with CNS directed gene therapy. We will administer an existing gene replacement vector (scAAV9-HsPEX16) to the brain of our mouse model, which will enter their cells and produce normal PEX16 protein. CNS characterization will then be repeated to determine preclinical efficacy. This project will help us understand the role of PEX16 in the CNS and the feasibility of gene therapy for treating PEX16-mediated ZSD. If effective, the therapeutic approach used in these experiments could be translatable to treating patients with other PEX gene mutations as well as other genetic diseases with CNS involvement.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gosaine, Amrita
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~